Developing Oral LT3 Therapy for Heart Failure - HFpEF
Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
Investigation of the safety, feasibility, and preliminary efficacy of thyroid hormone therapy
with Liothyronine (LT3) in individuals with heart failure with preserved ejection fraction
(HFpEF) and low triiodothyronine (T3) syndrome by conducting a randomized, double-blind,
placebo-controlled cross-over study with a two-week washout period between treatments.